AN2 Therapeutics, Inc. (ANTX)

Market Cap	70.85M
Revenue (ttm)	n/a
Net Income (ttm)	-64.73M
Shares Out	29.77M
EPS (ttm)	-2.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142,267
Open	2.480
Previous Close	2.480
Day's Range	2.360 - 2.520
52-Week Range	2.370 - 22.220
Beta	-0.24
Analysts	Hold
Price Target	6.50 (+173.11%)
Earnings Date	May 9, 2024

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX

Analyst Forecast

According to 4 analysts, the average rating for ANTX stock is "Hold." The 12-month stock price forecast is $6.5, which is an increase of 173.11% from the latest price.

Price Target

$6.5

(173.11% upside)

Analyst Consensus: Hold